Summary
None of the provided AI claims are supported or evaluated against the supplied FDA label excerpts because the excerpts include only contraindications and thyroid C-cell tumor warnings/counseling; the AI claims are primarily about gastric emptying, meal timing, and adverse effects that are not present in the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Ozempic (semaglutide) slows gastric emptying.
Not supported by the supplied label excerpts (provided sections cover only thyroid C-cell tumor warning/counseling and contraindications).
Slowed gastric emptying delays how quickly food leaves the stomach.
Not supported by the supplied label excerpts.
Slowed gastric emptying reduces post-meal blood sugar spikes.
Not supported by the supplied label excerpts.
Ozempic promotes fullness.
Not supported by the supplied label excerpts.
Ozempic may lead users to adjust meal timings for better tolerance.
Not supported by the supplied label excerpts.
Patients commonly space meals 4–6 hours apart to avoid nausea or bloating from overlapping digestion.
Not supported by the supplied label excerpts.
Ozempic is a GLP-1 receptor agonist.
The supplied label excerpts do not state this.
As a GLP-1 receptor agonist, Ozempic mimics gut hormones that signal the stomach to empty more slowly.
Not supported by the supplied label excerpts.
Studies show Ozempic can extend gastric emptying time by 20–50% after meals.
Not supported by the supplied label excerpts.
The extension of gastric emptying time by Ozempic is especially for fats and proteins.
Not supported by the supplied label excerpts.
The gastric emptying effect of Ozempic peaks 1–3 hours post-injection.
Not supported by the supplied label excerpts.
The gastric emptying effect stabilizes with weekly dosing.
Not supported by the supplied label excerpts.
Ozempic dose varies (0.25 mg starting up to 2.4 mg).
The supplied label excerpts do not include dosage/strength escalation information.
Some patients skip or delay breakfast if still full from dinner, eating the first meal around noon.
Not supported by the supplied label excerpts.
Extending the lunch-to-dinner gap to 5–7 hours helps prevent discomfort.
Not supported by the supplied label excerpts.
Avoiding late-night eating helps prevent worsening reflux or indigestion.
Not supported by the supplied label excerpts.
In clinical trials (e.g., SUSTAIN), 20–30% of users adapt meal timings within weeks to manage side effects like nausea.
Not supported by the supplied label excerpts.
In the SUSTAIN program, nausea incidence is 44%.
Not supported by the supplied label excerpts.
Tight meal schedules (meals less than 3 hours apart) increase nausea and vomiting.
Not supported by the supplied label excerpts.
Tight meal schedules (meals less than 3 hours apart) increase gastroparesis-like symptoms.
Not supported by the supplied label excerpts.
Tight meal schedules cause increased symptoms in 5–10% of users.
Not supported by the supplied label excerpts.
A trial found higher dropout rates without spacing meals.
Not supported by the supplied label excerpts.
Hypoglycemia risk rises if meal timings clash with oral medications.
Not supported by the supplied label excerpts.
Delayed gastric absorption from Ozempic affects oral medications.
Not supported by the supplied label excerpts.
Starting with smaller, low-fat meals at consistent times helps with meal timing on Ozempic.
Not supported by the supplied label excerpts.
Hydrating between (not during) eating is recommended for meal timing on Ozempic.
Not supported by the supplied label excerpts.
Tracking symptoms and adjusting if nausea occurs is recommended for meal timing on Ozempic.
Not supported by the supplied label excerpts.
Doctors recommend 3 meals per day over snacking while on Ozempic.
Not supported by the supplied label excerpts.
The effect of Ozempic on gastric emptying lessens slightly over time but persists.
Not supported by the supplied label excerpts.
Gastric effects of Ozempic build over 4–8 weeks.
Not supported by the supplied label excerpts.
The gastric effects of Ozempic peak by month 2.
Not supported by the supplied label excerpts.
Some effects normalize after 6 months.
Not supported by the supplied label excerpts.
30–40% of people need permanent changes.
Not supported by the supplied label excerpts.
Stopping Ozempic reverses the gastric effect within days.
Not supported by the supplied label excerpts.
Contradictions
Important Omissions
Any mention of the supplied label’s contraindications (personal/family history of medullary thyroid carcinoma or MEN 2) and associated boxed/warning counseling about thyroid C-cell tumor risk/symptoms.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims are not supported by the supplied label excerpts; however, no direct contraindication or dosing instructions are given in the AI claims that conflict with the supplied contraindications. Still, unsupported guidance about meal timing/nausea/medication effects could mislead, so alignment to the provided label is poor.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims (gastric emptying kinetics, meal timing strategies, trial-based percentages) are not supported by the supplied FDA label excerpts.
Suggested Improvement
Limit statements to information present in the provided label sections (contraindications for MTC/MEN 2 and thyroid C-cell tumor warning/counseling), or provide the corresponding FDA label sections that address gastric emptying, dosing, adverse reactions, drug interactions, and patient counseling for meal timing.